PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion

Biochemical and Biophysical Research Communications

Volumn 390, Issue 4, 2009, Pages 1288-1293

  Langhi, Cédric ^a   Le May, Cédric ^a   Gmyr, Valéry ^a,d   Vandewalle, Brigitte ^a,d   Kerr Conte, Julie ^a,d   Krempf, Michel ^a,b,c   Pattou, François ^a,d   Costet, Philippe ^a,c   Cariou, Bertrand ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c L INSTITUT DU THORAX   (France)

^d UNIV LILLE   (France)

Author keywords

Cholesterol; Diabetes; Insulin secretion; LDL receptor; Somatostatin

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SOMATOSTATIN; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INCUBATION TIME; INSULIN RELEASE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET DELTA CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STREPTOZOCIN DIABETES;

ANIMALS; CELL LINE; CHOLESTEROL; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MICE; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; SOMATOSTATIN-SECRETING CELLS;

MUS;

EID: 70450267457     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.138     Document Type: Article

References (26)

1. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., and Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 100 (2003) 928-933
2. Costet P., Krempf M., and Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem. Sci. 33 (2008) 426-434
3. Kwon H.J., Lagace T.A., McNutt M.C., Horton J.D., and Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. USA 105 (2008) 1820-1825
4. Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., Cohen J.C., and Hobbs H.H. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282 (2007) 18602-18612
5. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derre A., Villeger L., Farnier M., Beucler I., Bruckert E., Chambaz J., Chanu B., Lecerf J.M., Luc G., Moulin P., Weissenbach J., Prat A., Krempf M., Junien C., Seidah N.G., and Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 (2003) 154-156
6. Cohen J.C., Boerwinkle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354 (2006) 1264-1272
7. Grupping A.Y., Cnop M., Van Schravendijk C.F., Hannaert J.C., Van Berkel T.J., and Pipeleers D.G. Low density lipoprotein binding and uptake by human and rat islet beta cells. Endocrinology 138 (1997) 4064-4068
8. Roehrich M.E., Mooser V., Lenain V., Herz J., Nimpf J., Azhar S., Bideau M., Capponi A., Nicod P., Haefliger J.A., and Waeber G. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J. Biol. Chem. 278 (2003) 18368-18375
9. Cnop M., Hannaert J.C., Grupping A.Y., and Pipeleers D.G. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 143 (2002) 3449-3453
10. Brunham L.R., Kruit J.K., Pape T.D., Timmins J.M., Reuwer A.Q., Vasanji Z., Marsh B.J., Rodrigues B., Johnson J.D., Parks J.S., Verchere C.B., and Hayden M.R. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13 (2007) 340-347
11. Brunham L.R., Kruit J.K., Verchere C.B., and Hayden M.R. Cholesterol in islet dysfunction and type 2 diabetes. J. Clin. Invest. 118 (2008) 403-408
12. Niesen M., Bedi M., and Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch. Biochem. Biophys. 470 (2008) 111-115
13. Costet P., Cariou B., Lambert G., Lalanne F., Lardeux B., Jarnoux A.L., Grefhorst A., Staels B., and Krempf M. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J. Biol. Chem. 281 (2006) 6211-6218
14. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., and Hobbs H.H. Plasma levels of PCSK9 in a large multiethnic population. J. Clin. Endocrinol. Metab. (2009)
15. Dubuc G., Tremblay M., Pare G., Jacques H., Hamelin J., Benjannet S., Boulet L., Genest J., Bernier L., Seidah N.G., and Davignon J. A new method for measurement of total plasma PSCK9-clinical applications. J. Lipid Res. (2009)
16. Rashid S., Curtis D.E., Garuti R., Anderson N.N., Bashmakov Y., Ho Y.K., Hammer R.E., Moon Y.A., and Horton J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA 102 (2005) 5374-5379
17. Ricordi C., Lacy P.E., Finke E.H., Olack B.J., and Scharp D.W. Automated method for isolation of human pancreatic islets. Diabetes 37 (1988) 413-420
18. Le May C., Chu K., Hu M., Ortega C.S., Simpson E.R., Korach K.S., Tsai M.J., and Mauvais-Jarvis F. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc. Natl. Acad. Sci. USA 103 (2006) 9232-9237
19. Hauge-Evans A.C., King A.J., Carmignac D., Richardson C.C., Robinson I.C., Low M.J., Christie M.R., Persaud S.J., and Jones P.M. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 58 (2009) 403-411
20. Alborn W.E., Cao G., Careskey H.E., Qian Y.W., Subramaniam D.R., Davies J., Conner E.M., and Konrad R.J. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin. Chem. 53 (2007) 1814-1819
21. Lagace T.A., Curtis D.E., Garuti R., McNutt M.C., Park S.W., Prather H.B., Anderson N.N., Ho Y.K., Hammer R.E., and Horton J.D. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116 (2006) 2995-3005
22. Zaid A., Roubtsova A., Essalmani R., Marcinkiewicz J., Chamberland A., Hamelin J., Tremblay M., Jacques H., Jin W., Davignon J., Seidah N.G., and Prat A. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48 (2008) 646-654
23. Le May C., Kourimate S., Langhi C., Chetiveaux M., Jarry A., Comera C., Collet X., Kuipers F., Krempf M., Cariou B., and Costet P. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 29 (2009) 684-690
24. Grefhorst A., McNutt M.C., Lagace T.A., and Horton J.D. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J. Lipid Res. 49 (2008) 1303-1311
25. Schmidt R.J., Beyer T.P., Bensch W.R., Qian Y.W., Lin A., Kowala M., Alborn W.E., Konrad R.J., and Cao G. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem. Biophys. Res. Commun. 370 (2008) 634-640
26. Rutti S., Ehses J.A., Sibler R.A., Prazak R., Rohrer L., Georgopoulos S., Meier D.T., Niclauss N., Berney T., Donath M.Y., and von E.A. Low and high-density lipoproteins modulate function, apoptosis and proliferation of primary human and murine pancreatic beta cells. Endocrinology (2009)